# Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy

> **NCT02647255** · PHASE2,PHASE3 · TERMINATED · sponsor: **Peking University First Hospital** · enrollment: 10 (actual)

## Conditions studied

- Glomerulonephritis, IGA
- Kidney Diseases
- Acute Renal Insufficiency
- Rapidly Progressive Glomerulonephritis

## Interventions

- **PROCEDURE:** Plasma Exchange (PE)
- **DRUG:** Methylprednisolone pulse

## Key facts

- **NCT ID:** NCT02647255
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2020-10
- **Final completion:** 2020-10
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Due to the rarity and rapid progressive course of the disease, patients were less likely to participate in randomization.
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02647255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02647255, "Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02647255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*